Form S-8 Taysha Gene Therapies,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Taysha Gene Therapies (TSHA) PT Lowered to $31 at Jefferies
April 1, 2022 8:46 AM EDTJefferies analyst Eun Yang lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $31.00 (from $41.00) while maintaining a Buy rating.
The analyst commented, "Prioritization of several key pipeline programs is positive (vs prior >20 gene therapy programs in development),... More
Taysha Gene Therapies (TSHA) PT Lowered to $37 at Oppenheimer
April 1, 2022 8:18 AM EDTOppenheimer analyst Kevin DeGeeter lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $37.00 (from $45.00) while maintaining a Outperform rating.
The analyst commented, "TSHA disclosed restructuring to focus on giant axonal neuropathy (GAN) and Rett syndrome, confirming suggestive comments at our 3/15 conference (note). Restructuring includes:... More
